Shionogi & Co., Ltd.

4507.T
Drug Manufacturers - Specialty & Generic
2026/11/20 13:29 Updated
Market Cap: $16.9B (¥2.7T)
Stock Price: $19.90 (¥3,159)
Exchange Rate: 1 USD = ¥158.73

Completion of Full Acquisition of U.S. IntraBio, Inc.

Announced completion of acquisition of IntraBio. Through expansion of the AQNEURSA neurological treatment portfolio and strengthening global capabilities in rare diseases, the company will expand its clinical development and commercial base in rare disease areas.

Importance:
Page Updated: November 18, 2026
IR Disclosure Date: November 18, 2026

Key Figures

  • AQNEURSA approval status: Approved by U.S. FDA / European EMA (adult & pediatric / with weight requirements), additional approval for A-T depends on FDA developments
  • Acquisition completion date: Announced October 5, 2026; disclosure of acquisition completion date and consolidated impact was incorporated into the revised forecast on October 29, 2026
  • Related disease programs: Initiation and continuation of Phase 3 trial for CACNA1A-related disorders

AI要約

Overview of the News

Shionogi & Co., Ltd. announced the completion of the full acquisition of U.S.-based IntraBio, Inc. This expands the AQNEURSA portfolio for NPC neurological symptoms and A-T ataxia treatments and strengthens the company’s global efforts in rare diseases. AQNEURSA is approved by the U.S. FDA and the European EMA; FDA approval for A-T patients was granted in September 2026.

Future Development and Outlook

Shionogi will continue and expand programs led by IntraBio, including the Phase 3 trial for CACNA1A-related disorders, and will assess clinical development opportunities in rare disease areas. Ongoing clinical development programs for Pompe disease, fragile X syndrome, and Jordan's syndrome will also continue to be advanced.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Shionogi & Co., Ltd.

Company overview · Stock price · Financial data · All IR

View company page →